PFIZER2022-10-012022-12-31 PFIZER2022-10-012022-12-31 PFIZER2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member PFIZER2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member PFIZER2022-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500680 PFIZER NA Pfizer Limited Equity 2022-04-01 2023-03-31 2023-02-09 2023-02-01 INR Crores Third quarter 14:45:00 16:30:00 2023-02-09 2023-02-09 Not applicable Single segment Pharmaceutical 2022-10-01 2022-12-31 Unaudited Standalone 6217500000.00 274100000.00 6491600000.00 899300000.00 798700000.00 474000000.00 916900000.00 38400000.00 263400000.00 1094100000.00 4484800000.00 2006800000.00 0.00 2006800000.00 518000000.00 -17800000.00 500200000.00 0.00 1506600000.00 0.00 0.00 0.00 0.00 1506600000.00 -1900000.00 1504700000.00 0.00 0.00 457500000.00 10 32.93 32.93 0.00 0.00 32.93 32.93 1.The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on February 09, 2023 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). 3.The financial results for the quarter and nine months ended December 31, 2022 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in 4.Net exceptional items aggregating Rs. 52.59 crore for the nine months period ended December 31, 2022 includes: a. Income of Rs. 188.92 crore on account of transfer of certain primarily off-patented and generic established medicines business (Upjohn Business) as a going concern together with its related business assets and liabilities to Mylan Pharmaceuticals Private Limited during the quarter ended September 30, 2022 b. Charge of Rs. 129.85 crore on account of Voluntary Retirement Scheme (VRS) and an additional charge of Rs. 6.48 crore (net) on account of restructuring to drive business transformation during the quarter ended June 30, 2022. Single segment 2022-04-01 2022-12-31 Unaudited Standalone 18521200000.00 696700000.00 19217900000.00 2746000000.00 3209600000.00 621000000.00 2663700000.00 108600000.00 791000000.00 3011000000.00 13150900000.00 6067000000.00 525900000.00 6592900000.00 1853900000.00 -203800000.00 1650100000.00 0.00 4942800000.00 0.00 0.00 0.00 0.00 4942800000.00 -5800000.00 4937000000.00 0.00 0.00 457500000.00 10 108.04 108.04 0.00 0.00 108.04 108.04 Other Expenses 1094100000.00 Other Expenses 3011000000.00 2600000.00 7800000.00 -700000.00 -2000000.00